Studies on estradiol depletion by aromatase inhibitors in subjects with postmenopausal breast cancer indicate that higher levels of aromatase activity associated with elevated adipose tissue mass, reduce the efficacy of aromatase inhibitor therapy [77]. Here, CYP19A1 is linked to breast cancer.